Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech IncfiledCriticalJanssen Biotech Inc
Publication of AR120492A1publicationCriticalpatent/AR120492A1/en
Se proporcionan vacunas, polipéptidos y polinucleótidos basados en secuencias de CALR y JAK2 mutantes, vectores, células huésped, virus, y métodos para elaborarlos y usarlos. La descripción también proporciona métodos para inducir una respuesta inmunitaria y métodos para tratar, prevenir, reducir el riesgo de aparición o retrasar la aparición de una situación clínica caracterizada por una expresión de la mutación JAK2V617F o exón 9 de CALR o tanto la mutación JAK2V617F como exón 9 de CALR, en donde el método comprende una pluralidad de administraciones de cualquiera de las composiciones que comprenden polinucleótidos, polipéptidos o vectores descritos en la presente descripción.Vaccines, polypeptides and polynucleotides based on mutant CALR and JAK2 sequences, vectors, host cells, viruses, and methods for making and using them are provided. The disclosure also provides methods for inducing an immune response and methods for treating, preventing, reducing the risk of onset, or delaying the onset of a clinical condition characterized by an expression of the JAK2V617F mutation or CALR exon 9 or both the JAK2V617F mutation and exon 9. 9 of CALR, wherein the method comprises a plurality of administrations of any of the compositions comprising polynucleotides, polypeptides, or vectors described herein.
ARP200103191A2019-11-182020-11-18
VACCINES BASED ON CALR AND JAK2 MUTANTS AND THEIR USES
AR120492A1
(en)
polynucleotide, vector, adenovirus, composition, cell, polypeptide, use thereof, and methods for inducing and eliciting an immune response and for prophylaxis or treatment in an individual.